8-K: Shuttle Pharmaceuticals Faces Nasdaq Delisting Notice Due to Delayed Financial Filings

Shuttle Pharmaceuticals received a notice from Nasdaq for non-compliance with listing rules due to a delay in filing its quarterly report, stemming from a re-audit of prior financial statements.

Summary

• Shuttle Pharmaceuticals received a notice from Nasdaq for not complying with listing rule 5250(c)(1).
• The non-compliance is due to the company's failure to file its Quarterly Report on Form 10-Q for the period ended June 30, 2024.
• This delay is a result of a re-audit of the company's 2022 financial statements, triggered by SEC sanctions against their previous auditor, B.F. Borgers CPA, PC.
• The company's current auditor, Forvis Mazars, LLP, is re-auditing the 2022 financials.
• Shuttle Pharma is preparing amended reports for the year ended December 31, 2023, and the quarter ended March 31, 2024, which will include restated financial information.
• The company anticipates filing these amended reports in the next several days.
• After filing the amended reports, the company expects to file the Q2 Quarterly Report and regain compliance with the listing rule.
• If additional time is needed, the company has 60 days to submit a compliance plan to Nasdaq and could receive up to 180 days to regain compliance.
• The Nasdaq notice does not immediately affect the listing of the company's stock.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the non-compliance notice, the need for a re-audit, and the delay in financial reporting. These issues raise concerns about the company's financial controls and governance.

Positives

• The company anticipates filing the amended reports in the next several days.
• The company expects to automatically regain compliance with the listing rule after filing the Q2 Quarterly Report.
• The Nasdaq notice has no immediate effect on the listing of the company's common stock.

Negatives

• The company is not in compliance with Nasdaq Listing Rule 5250(c)(1).
• The company failed to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024.
• The delay is due to a re-audit of the 2022 financial statements, which is a significant undertaking.
• The company needs to file amended reports for 2023 and Q1 2024, indicating a material issue with previous financial statements.

Risks

• There is a risk that the company may not be able to file the amended reports and the Q2 Quarterly Report in the anticipated timeframe.
• If the company requires additional time, it will need to submit a compliance plan to Nasdaq within 60 days.
• There is a risk that the company may not be able to regain compliance within the allowed timeframe, potentially leading to delisting.
• The re-audit and restatement of financial statements could reveal further issues or require additional adjustments.

Future Outlook

The company anticipates filing amended reports in the next several days and expects to regain compliance with Nasdaq listing rules after filing the Q2 Quarterly Report. If needed, they will submit a compliance plan within 60 days and could receive up to 180 days to regain compliance.

Management Comments

• The company is working to file the amended reports and the Q2 Quarterly Report as soon as possible.
• The company expects to automatically regain compliance with the listing rule after filing the Q2 Quarterly Report.

Industry Context

This situation highlights the importance of maintaining accurate and timely financial reporting, especially for publicly traded companies. The SEC's sanctions against the previous auditor underscore the regulatory scrutiny that companies and their auditors face. Delays in financial reporting can lead to significant consequences, including potential delisting from exchanges.

Comparison to Industry Standards

• The delay in filing financial reports is a significant deviation from industry standards for publicly listed companies.
• Most companies listed on Nasdaq are expected to file their quarterly reports within a specified timeframe, typically 45 days after the end of the quarter.
• The re-audit and restatement of financial statements are not common occurrences and indicate a serious issue with the company's previous financial reporting.
• Companies like Amarin Corporation and Cassava Sciences have faced similar issues with restatements and auditor changes, which led to significant market volatility and scrutiny.

Stakeholder Impact

• Shareholders may experience uncertainty and potential volatility in the stock price due to the non-compliance notice and delayed financial reporting.
• Employees may be concerned about the company's financial stability and future prospects.
• Creditors and suppliers may reassess their relationships with the company due to the financial reporting issues.

Next Steps

• The company will file amended reports for the year ended December 31, 2023, and the quarter ended March 31, 2024.
• The company will file the Q2 Quarterly Report for the period ended June 30, 2024.
• If needed, the company will submit a compliance plan to Nasdaq within 60 days.
• The company will work to regain compliance with Nasdaq listing rules.

Key Dates

Keywords

Nasdaq, non-compliance, delisting, financial statements, re-audit, SEC, quarterly report, Form 10-Q, Form 10-K, Shuttle Pharmaceuticals